DK3474822T3 - Formuleringer af brincidofovir - Google Patents

Formuleringer af brincidofovir

Info

Publication number
DK3474822T3
DK3474822T3 DK17737695.1T DK17737695T DK3474822T3 DK 3474822 T3 DK3474822 T3 DK 3474822T3 DK 17737695 T DK17737695 T DK 17737695T DK 3474822 T3 DK3474822 T3 DK 3474822T3
Authority
DK
Denmark
Prior art keywords
brincidofovir
formulations
Prior art date
Application number
DK17737695.1T
Other languages
English (en)
Inventor
Irma Marisa Grossi
Mohammed Anowrul KABIR
Odin Johann Naderer
Original Assignee
Emergent Biodefense Operations Lansing Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Biodefense Operations Lansing Llc filed Critical Emergent Biodefense Operations Lansing Llc
Application granted granted Critical
Publication of DK3474822T3 publication Critical patent/DK3474822T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK17737695.1T 2016-06-28 2017-06-28 Formuleringer af brincidofovir DK3474822T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662355844P 2016-06-28 2016-06-28
US201662394665P 2016-09-14 2016-09-14
US201762446213P 2017-01-13 2017-01-13
US201762465053P 2017-02-28 2017-02-28
US201762507397P 2017-05-17 2017-05-17
US201762512825P 2017-05-31 2017-05-31
PCT/US2017/039804 WO2018005676A1 (en) 2016-06-28 2017-06-28 Formulations of brincidofovir

Publications (1)

Publication Number Publication Date
DK3474822T3 true DK3474822T3 (da) 2025-08-18

Family

ID=59313330

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17737695.1T DK3474822T3 (da) 2016-06-28 2017-06-28 Formuleringer af brincidofovir

Country Status (11)

Country Link
US (3) US20170368082A1 (da)
EP (2) EP4295853A3 (da)
JP (3) JP6878473B2 (da)
CN (4) CN119139329A (da)
AU (2) AU2017290703B2 (da)
DK (1) DK3474822T3 (da)
ES (1) ES3037596T3 (da)
FI (1) FI3474822T3 (da)
PL (1) PL3474822T3 (da)
PT (1) PT3474822T (da)
WO (1) WO2018005676A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073148A1 (en) * 2013-11-15 2015-05-21 Chimerix Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters
CN119139329A (zh) * 2016-06-28 2024-12-17 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途
CN114558022B (zh) * 2022-02-16 2023-11-17 华中农业大学 布林西多福韦在制备抗伪狂犬病毒药物中的应用
CN114732821A (zh) * 2022-04-24 2022-07-12 华中农业大学 西多福韦的前药在制备防治非洲猪瘟药物中的应用
JP7417339B1 (ja) * 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
WO2025072782A1 (en) * 2023-09-29 2025-04-03 Symbio Pharmaceuticals Limited Brincidofovir for treatment of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU785355B2 (en) 1999-12-03 2007-02-01 Regents Of The University Of California At San Diego, The Phosphonate compounds
JP4136340B2 (ja) * 2000-08-18 2008-08-20 武田薬品工業株式会社 注射剤
JP2008538354A (ja) 2005-04-08 2008-10-23 キメリクス,インコーポレイテッド ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
MX2009011573A (es) * 2007-04-27 2010-01-20 Chimerix Inc Metodos de reduccion de nefrotoxicidad en sujetos administrados con nucleosido.
JP2011116658A (ja) * 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
US20120164104A1 (en) 2009-08-03 2012-06-28 Chimerix, Inc. Composition and Methods of Treating Viral Infections and Viral Induced Tumors
JP2013509433A (ja) 2009-10-30 2013-03-14 キメリクス,インコーポレイテッド ウイルス関連疾患を処置する方法
PL2508170T3 (pl) 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
EP2611818B1 (en) 2010-08-31 2016-08-24 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
EP2770834A4 (en) * 2011-10-26 2015-11-25 Chimerix Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
US20150087619A1 (en) 2012-04-27 2015-03-26 Chimerix, Inc. Method of mitigating virus associated end-organ damage
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015073148A1 (en) * 2013-11-15 2015-05-21 Chimerix Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters
CN119139329A (zh) * 2016-06-28 2024-12-17 应急生物防御行动兰辛有限责任公司 布林西多福韦的制剂

Also Published As

Publication number Publication date
PL3474822T3 (pl) 2025-11-03
CA3024886A1 (en) 2018-01-04
ES3037596T3 (en) 2025-10-03
PT3474822T (pt) 2025-08-21
EP4295853A3 (en) 2024-03-06
US12485131B2 (en) 2025-12-02
EP4295853A2 (en) 2023-12-27
JP7221485B2 (ja) 2023-02-14
US20170368082A1 (en) 2017-12-28
US20230210873A1 (en) 2023-07-06
EP3474822B1 (en) 2025-07-09
AU2023204117A1 (en) 2023-07-13
CN109475497A (zh) 2019-03-15
CN118416082A (zh) 2024-08-02
AU2023204117B2 (en) 2025-03-20
CN119139329A (zh) 2024-12-17
JP6878473B2 (ja) 2021-05-26
AU2017290703A1 (en) 2018-12-13
US20200138835A1 (en) 2020-05-07
JP2019519570A (ja) 2019-07-11
EP3474822A1 (en) 2019-05-01
FI3474822T3 (fi) 2025-08-15
CN114569547A (zh) 2022-06-03
WO2018005676A1 (en) 2018-01-04
JP2023033538A (ja) 2023-03-10
JP2021143178A (ja) 2021-09-24
JP7407984B2 (ja) 2024-01-04
AU2017290703B2 (en) 2023-03-30

Similar Documents

Publication Publication Date Title
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
EP3534968A4 (en) ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3554240T3 (da) Kombinationer af aktive forbindelser
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3185853T3 (da) Inhalerbare pulverformuleringer af alginatoligomerer
DK3457851T3 (da) Derivater af sobetirom
EP3406336A4 (en) NANO FOIL OF CORE CASE STRUCTURE TYPE
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3220891T3 (da) Sublingual formulering af riluzol
DK3798222T3 (da) Krystallinsk form af den frie base af lorlatinib
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
EP3364945C0 (en) SOLID FORMULATION
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3307267T3 (da) Behandling af multipel sklerose
DK3697418T3 (da) Forbedrede formuleringer af bromocriptin
DK3418273T3 (da) Derivater af flavagliner
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3511000T3 (da) Krystallinsk form x2 af grapiprant
DK3678644T3 (da) Formuleringer af copanlisib